The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
about
Deep Response in Multiple Myeloma: A Critical ReviewNew criteria for response assessment: role of minimal residual disease in multiple myelomaMyeloma today: Disease definitions and treatment advances.Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life studyMultiple myeloma: 2016 update on diagnosis, risk-stratification, and management.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsMultiple Myeloma Minimal Residual Disease.Standardisation of minimal residual disease in multiple myeloma.Current applications of multiparameter flow cytometry in plasma cell disorders.Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
P2860
Q26771228-2488F819-C6B6-4C39-A0AE-122666ADCFFDQ27027512-A11B32D4-E943-4C3B-AD50-237E2454CCA1Q36470699-25F08718-3D27-448C-B397-59720817E66CQ36705534-2A03B5E4-82C1-47C1-8202-731518F3FA0AQ37623809-A3F2CFB4-8B7A-48A7-A03A-99CF76D2DFA6Q38534837-985FF568-F455-4ED6-B26F-A78D5821BACCQ38543122-F546DDF8-2147-446E-BB00-83EE53BFD362Q38756800-D7575D18-B558-4839-B384-98B844CCF6A3Q38789282-6C87C17F-4442-4BE6-8FE1-1D19C65C76DCQ38970590-E23F8095-0941-4E65-AD4A-20EA2208BA78Q39410899-56DE83A7-0500-4125-957E-44149A293AE2Q47110039-48C527DB-F010-4870-BF44-339E0054D215Q47281717-4CBC43D6-4FCA-4035-8072-504A98AF848BQ47307819-F0EC5ED9-7F5E-4AD3-A1BD-94975A5EA447Q47369825-01BD1D91-B2B4-4CDC-ABF3-1F8C1D27208F
P2860
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The prognostic value of multip ...... in relapsed multiple myeloma.
@en
The prognostic value of multip ...... in relapsed multiple myeloma.
@nl
type
label
The prognostic value of multip ...... in relapsed multiple myeloma.
@en
The prognostic value of multip ...... in relapsed multiple myeloma.
@nl
prefLabel
The prognostic value of multip ...... in relapsed multiple myeloma.
@en
The prognostic value of multip ...... in relapsed multiple myeloma.
@nl
P2093
P2860
P50
P1433
P1476
The prognostic value of multip ...... t in relapsed multiple myeloma
@en
P2093
Ana Jimenez-Ubieto
Bruno Paiva
Jose J Perez
Juan-José Lahuerta
Lucia Lopez-Corral
Maria-Belen Vidriales
Maria-Victoria Mateos
Mauricio Chandia
Noemi Puig
P2860
P356
10.3324/HAEMATOL.2014.115162
P577
2014-11-07T00:00:00Z